FI84723B - FORM OF THERAPEUTIC ACTIVATION OF 2- (1,8-NAPHTHYRIDIN-2-YL) -ISOINDOLIN-1-ONER. - Google Patents

Abstract

Derivatives of formula (I), in which A forms with the pyrrole ring an isoindoline, 6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine, 2,3,6,7- tetrahydro-5H-oxathiinno[1,4][2,3C]pyrrole or 2,3,6,7-tetrahydro-5H- dithiinno[1,4][2,3C]pyrrole nucleus and Het = naphthyridinyl, pyridyl or quinolyl which are unsubstituted or substituted by a halogen, alkyl (1-4 C), alkoxy (1-4 C), alkylthio (1-4 C) or CF3, and R = alkenyl (3- 10 C) with a straight or branched chain or alkyl which is unsubstituted or substituted by alkoxy, alkylthio, cycloalkyl (3-6 C), NH2, alkylamino, dialkylamino, alkylcarbonylamino (in which the amino part is optionally alkyl-substituted), 1- or 2-piperazinyl, piperidyl, piperidino, morpholino, pyrrolidinyl, 1-azetidinyl, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, (1-piperazinyl)carbonyl, piperidinocarbonyl, (1-pyrrolidinyl)carbonyl, phenyl, pyridyl, 1- imidazolyl, or else R = 2- or 3-pyrrolidinyl or 2-,3- or 4-piperidyl, it being understood that the alkyl radicals form a straight or branched chain and, unless specially mentioned, contain 1 to 10 C and that the piperazinyl, piperidino, piperidyl, pyrrolidinyl and azetidinyl radicals may be unsubstituted or substituted in any position by alkyl, alkylcarbonyl, benzyl or hydroxyalkyl or else may form a lactam functional group with the nitrogen atom of the ring, and, when they exist, their pharmaceutically acceptable salts and the optical isomers of the products of formula (I). <IMAGE> The products of formula (I) are useful as anxiolytics.

Description

1 84723

Process for the preparation of therapeutically active 2- (1,8-naphthyridin-2-yl) -isoindolin-1-ones

The invention relates to a process for the preparation of therapeutically active 2- (1,8-naphthyridin-2-yl) -isoindolin-1-ones of formula (I)

Oy-CO "-

OCOR

Wherein R is a C 1-7 alkyl group which may be substituted by an alkoxy or dialkylamino group or an alkylcarbonylamino group, the amino moiety of which may be substituted by a C 1-7 alkyl, piperidino or piperidyl group, or R is 4-piperidyl, wherein the alkyl groups are straight-chain or branched and the piperidino and 4-piperidyl group may be substituted with one or two alkyl groups and Rx is a halogen atom or a C1-4 alkyl or C1-4 alkoxy group, and for the preparation of pharmaceutically acceptable acid addition salts and optical isomers thereof.

A. According to the invention, compounds of formula (I) wherein R is as defined above and Rx is a halogen atom can be prepared by reacting an acid of general formula (II) R-COOH (II) or an alkali metal salt thereof, wherein R is as defined above. above, to react with a compound of general formula (III): 358 82323 o γΛ ^ 5 Γ jl ^ - R1 (III) ci wherein R'x is a halogen atom or an alkyl group.

In general, a condensing agent such as 1,8-diazabicyclo [5.4.0] undec-7-ene or 1,5-diazabicyclo [5.3.0] non-5-ene or a quaternary ammonium hydroxide such as triethylbenzylammonium hydroxide is used. in the presence of an organic solvent such as dimethylformamide at a temperature of 20 ° C to 100 ° C, or, when an alkali metal salt of an acid is used, simply in dimethylformamide at a temperature of 20 ° C.

Compounds of general formula (III) may be prepared by chlorination of a compound of general formula: 20: 0 1 - -1OCr

OH

30 wherein R'j is as defined above.

Generally, a chlorinating agent such as sulfinyl chloride or phosphorus oxychloride and a catalytic amount of dimethylformamide is operated between about 20 ° C and the reflux temperature of the reaction mixture, or any other 3,84723 substance known to those skilled in the art which allows the radical to be substituted without .

Compounds of general formula (IV) may be prepared using or applying the methods set out in BE Patents 815,019 or 835,325.

B. According to the invention, compounds of general formula (I) in which R and ^ are as defined above can be prepared by reacting a derivative of general formula (V) RCO-X (V) in which R is as defined above and X is a halogen atom, such as chlorine or a reactive ester residue, to react with a compound of formula (IV) J ”CO Tr:‘ ™

: OH

25 wherein Rx is as defined above.

The reaction is generally carried out in an organic solvent such as chloroform or methylene chloride or in an ether such as tetrahydrofuran or dioxane at a temperature between 0 ° C and the reflux temperature of the reaction mixture: in the presence of a base such as sodium hydride or triethylamine or pyridine.

C. According to the invention, compounds of general formula (I) in which R and R 1 have the same meaning as above can be prepared by reacting an alkali metal salt of an acid 4,84723 of general formula (II) with a compound of formula (VI)

Oy ”hOO- ™ 0-P- (OR) I * 4 2 10 0 wherein R4 is a straight-chain or branched alkyl radical or a phenyl radical having 1 to 4 carbon atoms and has the same meaning as above.

It is generally carried out in an organic solvent such as dimethylformamide at a temperature of about 0 ° C to -25 ° C.

Compounds of general formula (VI) may be prepared by reacting a compound of general formula (VII): C1-J (OR4) 20 (VII) in which R4 is a straight-chain or branched alkyl radical or a phenyl radical having 1 to 4 carbon atoms, reacting a compound of general formula (IV) ) wherein R: is as defined above.

Generally, the reaction is carried out in an organic solvent such as dimethylformamide in the presence of an alkali metal hydride-like base such as sodium hydride at a temperature of about -5 ° C to + 25 ° C.

It is not necessary to isolate a compound of general formula (VI) when using the method of the invention. It is sufficient to condense the compounds of the general formulas (VII) and (IV) as will be shown, after which the alkali metal salt of the acid 5,84723 of the general formula (II) is added to the reaction mixture.

As will be appreciated by those skilled in the art, certain radicals included in the definition of the R symbol are incompatible with the reagents used in the reaction, and it is therefore necessary to protect them before performing the above methods or certain process steps. This is especially true when the radical R contains primary or secondary amine groups or hydroxyl groups which may allow secondary reactions with metal hydrides or halogen reagents. In these cases, the above groups must be protected using all methods known to those skilled in the art, whereby the protection is removed after the reaction.

The novel compounds of general formula (I) can be purified using customary known methods, for example by crystallization, chromatography or successive measurements in an acidic or basic environment.

The novel compounds of the general formula (1) can be converted into acid addition salts by using an acid dissolved in water or an organic solvent such as an alcohol, ketone, ether or chlorinated solvent. The salt formed precipitates, possibly after concentrating the solution; it is separated by filtration or decantation.

The compounds of general formula (I) have particularly interesting pharmacological properties having anxiolytic, anticonvulsant, antiepileptic and myo-relaxing activity. Thus, they show good Affi-30 activity in vitro for benzodiazepine receptor sites at a concentration of the order of 0.4 to 200 nM, using the method described in J.C. Inspired by Blanchard and L. Julou, J. of Neurochemistry, 40, 601 (1983), Squires and Braestrup, Nature, 266, 732 (1977).

6 84723

In animals (mice), they have been shown to be active against pentetrat-Sol-induced convulsions, as described in Everett and Richards, J. Pharmacol., 81, 402 (1944), at doses generally ranging from 3 to 200 mg / kg orally.

In addition, the compounds of general formula (I) and their salts show low toxicity. They generally have an LD50 higher than 300 mg / kg when administered orally to mice.

10 Pharmacological comparative tests

Toxicity The maximum dose (DL50) of test compound that orally kills 50% of mice was determined.

15 Affinity for key receptor sites for benzodiazepines

The technique is described in Squires et Braes-trup, Nature, 266, 732-734 (1977). Accordingly, the specific binding of tritiated flunitrazepam, a ligand for benzodiazepine-20 receptors, is measured in the presence of a test compound. If the compound has an affinity for benzodiazepine receptor sites, then the specific attachment of the ligand is reduced.

·. The experimental procedure is as follows: mixing and homogenized (2 centrifugations of 50,000 g) the whole cortex of 25 male rats (CD, COBS, Charles River, France) in 50 mM Tris-HCl pH 7.4 (final concentration 0.1 mg / ml protein), test compound at various concentrations and tritiated flunitrazepam (final concentration 1.5 nM). Non-30 specific binding is determined in the presence of diazepam (10 μΜ). The sample is incubated for 120 min at 0 ° C and then the sample is filtered through a glass fiber filter (Whatman GF / B) and the radioactivity remaining as a filter is measured using a liquid scintillation. The CI50 is the concentration at which the test compound inhibits 50% of the specific binding of the ligand.

Pentetrazole-induced convulsions

Mice weighing 18 to 22 g are used for the experiments. Each mouse is administered subcutaneously 150 mg / kg pentetrazole (unit dose / kg body weight in 25 ml solution). The test substance is administered orally 24 (or 6) hours before pentetrazole administration. Use 5 mice per dose and 3 doses per test substance.

After injection of pentetrazole, the mice are placed in a box divided into 15 compartments of 13 cm in length, with each mouse isolated throughout the observation period. The box is covered with a transparent plastic film. Mice in the control group given only 150 mg / kg penetrazole subcutaneously show more or less severe convulsions in less than 15 minutes, leading to rapid death. Experimental animals in the test group are observed for 30 minutes after pentetrazole injection. Test substance 20 is considered to have a protective effect unless convulsions occur during this 30 minute observation period. The DA50 dose inhibits pentetrazole-induced convulsions in 50% of animals.

Ripustamiskoe

Mice are placed on a horizontal metal wire drawn from the forelegs. If the animal fails to hang on the wire after three attempts, or if the animal hangs on the wire falls within 5 seconds or less, the animal is considered to have been subjected to a neuromuscular depressive effect; all control animals hang easily on the wire, remain attached to it, and even return to equilibrium in 5 seconds or less so that at least one hind leg touches the wire (pull test). 3 or 4 mice per dose and 2 to 5 doses per test subject are used. DAS0 is the dose with neuromuscular β 84723 depressive activity in 50% of animals.

Enzymatic induction

The technique is described in F. Scrollini et al., Arznaim. Forschung 25, 934-940, (1975).

5 Dogs weighing 18 to 24 g are used for the experiments! female mice (CD ^ COBS, Charles River, France). The test compound is administered orally once daily for four days at 25 cm 3 / kg.

After 24 hours, mice are given 75 mg / kg hexo-10 barbital by intravenous injection. During the two or three minutes following the injection, the mice are placed on their backs in an enclosed space maintained at a constant temperature of 28 ° C by means of a thermostat. The duration of anesthesia is measured and awakening is assessed as the occurrence of a straightening reflex. Enzymatic induction is assessed as a shortening of the anesthesia time, (statistical analysis: Student's t-test).

The results are shown in the following table.

ό 9 84723. ή m ή ι 'ο. o οοοο o οοοοοο ts -ρ I · Η g o in Ti Ti Ti t — i Ti Ti Ti Ti Ti Ti Ti v o

>, .μ -H -H O) rH -H

ϋ) · μ_Ρ. * Ι I II I I I I I I I I p P (0 C \ I a;> i C m S 3 oi m w ω co w w ui tn ui vi t / ι <o 3 e

UGGxJEz 2 2 2 2 2 222222 (Ό Ό G

G -H

• H -H

(0 (0 0)

P

-v. -H 0) -H

G H τΗ dl

CD O P

G CO PC

-HP (0 -H

E (0 (0 0 <op e «h p p oo Sh aitoa) v o oo o oo οί oo coo Ό 3 P in 00 CD 00 O 00 H O H 00 O ΡΌ

£ ac ^ 00 H OH

3-h a) vo o O rH o t — t in in 01 '

UI k a ΛΙ AI Ti ΛΙ VO Η ΛΙ ΛΙ Λ ΛΙ CO A rH VI S 'S' O 'AI AI rH P

S 3

S G

P 3

I CP

CO -H -HP

-H P O -H 3 E -h · in O O co 3

G-h Oi tn o oo O in 01E

P .C (N <N 00 in 00

CO · - O) OOO OOOOOOO OO O G -H

3 O O G O OOOOOO CO G G GOO m O -H P

Oi a) θ 'H -H O' OCOOiOOIO-HOi-Hrl-rlOOl OI CT> O CO

• HOMO) OOOO 0000 - H KU

M Λί Q E ΛΙ ΛΙ G ΛΙ 00 H ΛΙ AI A ΛΙ A Λ G VI G G G ΛΙ ΛΙ CN A H> O Λ)

o P

H P

r — I k -H

O ~ P X

CO -H 3 P

p ρ o Cai

(0 -h in in in in 3E

P -h O in in in s oo σ '* ή es p p .e o - v * · o>) o m oo «h v es v e ai a) w O) mootninOiHvocNino-tNiHCNcoOHOcNoj o es ai h

P nX HO

G ai <0 ai o H O) h a. X a e g ai o

G

Il G H

H 0) 0 -H -H

P UI P ^ -H H

Ρ P OiS H H

ai co ai e ho ai -h m w op ρ ό ai oo ρ p

h o P G in oo in oo oo in ο- PC

GW-H-H * vk *. kv «-C0

• h p c £ ooHincococoiorsvocAO'ioinooinocNCJ'oo o o 0 X

PC -H -H H (S 00 00 00 O S '00 O O H rH rH X

P 01 Ή 01 rH rH rH (0

<xi o. p co G

A G 3

3 P

P P ·

O O O O O O O O O O O O O O O O O O O 1 O PP

• O 'O'O'O'O'O'O'O'O'O'O'O'O'O'O'O'O'O' O 'O' P a) -h co oo ai> p

3 · GOCCCCCCCCCCGCCCGCG G G> X

3— Oi O00OOOOOOOOOOOOOOOOO O O 03 CO-H P PPPPPPPPPPPPPPPPP ρ ρ o Ρ Ό

• PP O) SiSSSSSSSSSSSSSSSSS S S P WC

CO-H * X XXXXXXXXXXXXXXXXX X X CO a) H

ϋΡ POPPPPPPPPPPPPPPPPP P P dl X

O.CJO> SOSSSSSSSSSSSSSSSSS S S X 10

E- «wQg EhEEEEEEEEEEEEEEEE E E CP

G H CO., LTD

• H CO · Η

I es en co Ο P

co σ> oo o O P

- P-H in Ti en h O <0 ai ai ^ h oo es o x p (0

(ΟΡΡΟ VO en P G E

X CO ai P OOHvDrHCNTivDISO'OOvnCSOOO '· Ti .in (0 CS

O H E G OOTivOISCTirHrHrHfSCSOslCSCSO ^ OOOOOOOOOO EH g vf G CD

ΗΌΉ -H H ·· P

3 G toafl nn «ui ·· ui e fsaip MOMDW20) 10 84723 The new products of the general formula (I) can be used as such or as pharmaceutically acceptable salts, i. in dosages as non-toxic salts.

Examples of pharmaceutically acceptable salts are addition salts of mineral acids, such as hydrochlorides, sulphates, nitrates, phosphates or salts of organic acids, such as acetates, propionates, succinates, benzoates, fumarates, maleates, isanesethanates, methanesulfonates, methanesulfonates, , phenolphthalates, methylene bis-β-oxynaphthoates and substituted derivatives of these compounds.

Of particular interest are compounds of formula I: 2- (7-chloro-1,8-naphthyridin-2-yl) -3-oxo-isoindolin-1-yl-4-acetamido-butyrate (-RS) 2- (7 -chloro-1,8-naphthyridin-2-yl) -3-oxo-isoindolin-2-yl-1-propionyl-4-piperidylcarboxylate (-RS) 2- (7-methoxy-1,8-naphthyridin-2-yl) 2-yl) -3-oxo-isoindolin-1-yl-5-methyl-hexanoate (-RS) 2- (7-chloro-1,8-naphthyridin-2-yl) -3-oxo-isoindolin-2-yl -yl 3-diisopropylamine propionate (-RS)

The following examples are provided by way of non-limiting example to illustrate how the invention may be practiced.

25 Example 1

To a solution of 16.5 g of 3-chloro-2- (7-chloro-1,8-naphthyridin-2-yl) -isoindolin-1-one in 100 cm 3 of dimethylformamide anhydride, kept under argon, was added about 20 ° C. in 9.2 g of 3-dimethylamine-30-propionic acid hydrochloride and 16.7 g of 1,8-diazabicyclo [5.4.0] undec-7-ene and the resulting suspension was shaken for 24 hours at about 20 ° C. 200 cm3 of distilled water and 200 cm3 of dichloromethane are then added. The aqueous phase is separated by decantation, followed by extraction 3 times with 50 cm3 of dichloromethane. The organic phases are combined, washed twice with 50 cm3 of distilled water, dried over magnesium sulphate, filtered and concentrated to dryness under reduced pressure (2.7 kPa) at 80 ° C. The residue obtained is dissolved in 100 cm3 of dichloromethane and the solution is extracted twice with 100 cm3 of 1N hydrochloric acid solution. The aqueous phases are combined, washed with 50 cm3 of dichloromethane, made alkaline by adding 10N sodium hydroxide solution until the pH is about 11 and extracted twice with 150 cm3 of dichloromethane. The organic phases are combined, washed twice with 30 cm3 of distilled water, dried over magnesium sulphate, filtered and concentrated to dryness under reduced pressure (2.7 kPa) at 60 ° C. Crystallized twice in succession in ethanol to give 2.9 g of 2- (7-chloro-1,8-naphthyridin-2-yl) -3-oxo-isoindolin-1-yl-3-dimethylamine-propionate-15-m.p. was 150 ° C.

3-Dimethylamine-propionic acid hydrochloride can be prepared using Clarke H.T., Gillespie H.B., Weisshaus S.Z., J. Am. Chem. Soc., 55, 4571 (1933).

3-Chloro-2- (7-chloro-1,8-naphthyridin-2-yl) -isoindolin-1-one can be prepared as follows: To 15.5 g of 3-hydroxy-2- (7- methoxy-1,8-naphthyridin-2-yl) -isoindolin-1-one was added dropwise with shaking 200 cm3 of sulfinyl chloride. The reaction mixture is refluxed with shaking for 1 hour, then 10.5 cm3 of dimethylformamide are added and refluxed again for 3 hours, then cooled to about 60 [deg.] C. and concentrated to dryness under reduced pressure (2.7 kPa) at 60 [deg.] C. :in. To the solid residue obtained, 100 cm3 of dichloromethane are added and the mixture is shaken for 10 minutes. The insoluble product is filtered off and washed first with 15 cm3 of dichloromethane and then twice with 25 cm3 of diisopropyloxide and air-dried. There was thus obtained 12.4 g of 3-chloro-2- (7-chloro-1,8-naphthyridin-2-yl) -isoin-35-dolin-1-one which did not melt at 300 ° C.

124723 3-Hydroxy-2- (7-methoxy-1,8-naphthyridin-2-yl) isoindolin-1-one can be prepared using the method described in BE Patent 815,019.

Example 2 The procedure was as in Example 1, but starting from 8.25 g of 3-chloro-2- (7-chloro-1,8-naphthyridin-2-yl) -isoindolin-1-one, 4.25 g of 4-dimethylamine -butyric acid hydrochloride and 7.6 g of 1,8-diazabicyclo [5.4.0] undec-7-ene to give 4.1 g of 2- (7-chloro-1,8-naphthyridin-10-2-yl) -3 -oxy-isoindolin-yl-4-dimethylamine-butanoate with a melting point of 148 ° C.

4-Dimethylamine-butyric acid hydrochloride can be prepared using the method described in C. Harries, F. Duvel, Li-bigs Ann. Chem., (1915) 410, 54.

15 Example 3

To a solution of 6.6 g of 3-chloro-2- (7-chloro-1,8-naphthyridin-2-yl) -isoindolin-1-one in 60 cm 3 of dimethylformamide anhydride, kept under argon, was added about 2.4 g of 4-methylpentanoic acid and 3.05 g of 1,8-diazabicyclo [5.4.0] undec-7-ene at 20 [deg.] C. and the resulting suspension was shaken for 24 hours at about 20 [deg.] C. . Then 200 cm3 of distilled water and 150 cm3 of dichloromethane are added. The aqueous phase is separated by decantation, then extracted twice with 150 cm3 of dichloromethane.

The organic phases are combined, washed 3 times with 50 cm3 of distilled water, dried over magnesium sulphate, filtered and concentrated to dryness under reduced pressure (2.7 kPa) at 60 ° C. The oily residue obtained was purified by chromatography on a 150 g silica gel column 3.5 cm in diameter (eluted with dichloromethane-methanol, 98: 2 by volume). Elution is first carried out with 200 cm3 of solvent and the corresponding eluate is removed, then the solvent is extracted with 900 cm3 and the corresponding eluate is concentrated to dryness under reduced pressure (2.7 kPa) at 35-40 ° C. Crystallized from ethanol to give 134723 4 g of 2- (7-chloro-1,8-naphthyridin-2-yl) -3-oxo-isoindolin-1-yl-4-methyl-pentanoate, m.p. 147 ° C. .

Example 4 The procedure was as in Example 1, but starting from 9.9 g of 3-chloro-2- (7-chloro-1,8-naphthyridin-2-yl) -isoindolin-1-one in 100 cm3 of dimethylformamide anhydride, 5.4 g of 1-methyl-3-piperidinecarboxylic acid hydrochloride and 10.7 g of 1,8-diazabicyclo [5.4.0] undec-7-10 ene, precipitated in 1000 cm3 of water, filtered and air-dried, to give 11.3 g of product with a melting point of 70 ° C. The solid obtained is dissolved in 40 cm3 of ethanol. To the hot solution was added 3 g of fumaric acid in 30 cm3 of ethanol. The crystallized product obtained is filtered off, washed with 15 cm3 of ethanol and dried under reduced pressure (0.07 kPa) at 45 ° C. There was thus obtained 9.8 g of 2- (7-chloro-1,8-naphthyridin-2-yl) -3-oxoisoindolin-1-yl-1-methyl-3-piperidinecarboxylate fumaric acid, with a melting point of 211 ° C.

20-Methyl-3-piperidinecarboxylic acid hydrochloride can be prepared as follows: 17.1 g of ethyl (1-methyl-3-piperidine) carboxylate were dissolved in 67 cm3 of 6N hydrochloric acid solution. Boil for 6 hours at reflux, after which the solution was concentrated to dryness and. The residue was crystallized from acetone. There was thus obtained 15.7 g of 1-methyl-3-piperidinecarboxylic acid hydrochloride, m.p. 186 ° C.

Example 5

The procedure was as in Example 1, but starting from 9.9 g of 3-chloro-2- (7-chloro-1,8-naphthyridin-2-yl) -isoindolin-1-one in 100 cm3 of dimethylformamide anhydride, 4 g of 1-methyl-4-piperidinecarboxylic acid hydrochloride and 10.7 g of 1,8-diazabicyclo [5.4.0] undec-7-ene, and the residue was crystallized twice, first in ethanol-35 and then in acetonitrile to give 5, 6 g of 144723 2- (7-chloro-1,8-naphthyridin-2-yl) -3-oxoisoindolin-1-yl-11-1-methyl-4-piperidinecarboxylate, first melting at 136 ° C, and then 157 ° C.

1-Methyl-4-piperidinecarboxylic acid hydrochloride can be prepared as described in Example 4 for 1-methyl-3-piperidinecarboxylic acid hydrochloride, but starting from the following substances: 8.6 g of ethyl (1-methyl-4-piperidine) - carboxylate and 33 cm 3 of 6N hydrochloric acid solution. Crystallization from acetone gave 6.5 g of 1-methyl-4-piperidinecarboxylic acid hydrochloride, m.p. 231 ° C.

Ethyl (1-methyl-4-piperidine) carboxylate can be prepared as follows: To a solution of 15.7 g of ethyl 4-piperidinecarboxylate dissolved in 8 cm 3 of water and kept at about 5 ° C: 20.3 cm 3 of a 37% (w / v) formaldehyde solution were added over 15 minutes at the same temperature, followed by 11.5 g of formic acid over 15 minutes. Boil under reflux for 4 hours, cool and adjust the pH to about 10 by adding 10 N sodium hydroxide solution. Extract 3 times with 150 cm of methylene chloride, wash the organic extracts with water, dry and concentrate to dryness under reduced pressure (2.7 kPa) at 70 ° C to give 13.5 g of ethyl (1-methyl-4-piperidine). carboxylate as an oil used in the synthesis shown as such.

Example 6

The procedure was as in Example 1, but starting from 9.9 g of 3-chloro-2- (7-chloro-1,8-naphthyridin-2-yl) -isoindolin-1-one in 70 cm3 of dimethylformamide anhydride, 4, 4 g of 3-diisopropylamine-propionic acid hydrochloride and 7.45 g of 8-diazabicyclo [5.4.0] undec-7-ene, and the residue was crystallized twice, first in acetonitrile, then in ethanol to give 2 g of 7.7 g of 2- (7-chloro-1,8-naphthyridin-2-yl) -3-oxy-isoindolin-1-yl-3-di-35-isopropylamine propionate, m.p. 13547, first 135 ° C.

3-Diisopropylamine-propionic acid hydrochloride can be prepared as described in Example 4 for 1-methyl-3-piperidinecarboxylic acid hydrochloride, but starting from: 5 g of ethyl 3-diisopropylamine-propionate and 35 cm3 6N hydrochloric acid solution. The obtained product was crystallized from acetone to give 2.3 g of 3-diisopropylamine-propionic acid hydrochloride, m.p. 170 ° C.

Ethyl 3-diisopropylamine propionate can be prepared as follows: over a period of 30 minutes, 18.1 g of ethyl 3-bromopropionate were added dropwise to a solution containing 28.5 cm 3 of diisopropylamine and 40 cm 3 of ethanol, and maintained at 25 ° C. Boiled at 15 reflux for 4 hours. The reaction mixture is then cooled and taken up in 100 cm3 of water and 70 cm3 of 4N hydrochloric acid solution. Wash with 100 cm3 of ethyl ether, then make alkaline to a pH of about 9 by adding 4N sodium hydroxide solution. The oil formed is extracted 3 times with 150 cm3 of methylene chloride. Wash twice with 100 cm3 of water and dry, after which the resulting chloromethylene solution is concentrated to dryness under reduced pressure (2.7 kPa) at 40 ° C. There was thus obtained 11.6 g of ethyl 3-diisopropylamine propionate as an oil, which was used as such in the synthesis shown.

Example 7

To a solution of 12.3 g of 2- (7-methoxy-1,8-naphthyridin-2-yl) -3-hydroxyisoindolin-1-one in 200 cm 3 of methylene chloride and kept at 20 ° C, 27 cm3 of triethylamine were added. Then, 10.8 g of 4-methylpentanyl chloride and 50 mg of 4-dimethylamine-pyridine were added dropwise over 20 minutes, after which the reaction mixture was refluxed for 19 hours. The suspension obtained is poured into 800 cm3 of water and the solid obtained; The material was filtered off and removed. The organic phase is decanted, washed with water, dried and concentrated to dryness under reduced pressure (2.7 kPa). The oily residue obtained is purified by chromatography on a 150 g silica gel column (0.063-0.2 mm) with a diameter of 2.7.5 cm and eluted with 50 cm3 fractions (methylene chloride). Fractions 6 to 18 are combined and concentrated to dryness under reduced pressure (2.7 kPa) at 40 ° C. The solid residue was crystallized from acetonitrile to give 4.9 g of 2- (7-methoxy-1,8-naphthyridin-2-yl) -3-oxo-isoindolin-1-yl-4-methyl-pentanoate. , melting point 133 ° C.

4-Methyl-pentanyl chloride can be prepared as described in F. Kogl and C.A. Salemink, Rec. Trav. Chim., 71, 779-97 (1952).

Example 8 The procedure was as in Example 1, but starting from 9.9 g of 3-chloro-2- (7-chloro-1,8-naphthyridin-2-yl) -isoindolin-1-one in 100 cm3 of dimethylformamide anhydride, 5.1 g of 1-acetyl-4-piperidinecarboxylic acid and 4.6 g of 1,8-diazabicyclo [5.4.0] undec-7-ene and crystallization were first crystallized from acetone-water (2: 1). by volume), and then in ethanol to give 7.5 g of 2- (7-chloro-1,8-naphthyridin-2-yl) -3-oxo-isoindolin-1-yl-1-acetyl-4-piperidyl- carboxylate with a melting point of 101 ° C.

: 25 Example 9

The procedure was as in Example 1, but starting from 9.9 g of 3-chloro-2- (7-chloro-1,8-naphthyridin-2-yl) -isoindolin-1-one per 100 cm3 of dimethylformamide anhydride, 3.9 g of 5-methyl-hexanoic acid and 4.6 g of 1,8-dia- ... 30-aza-bicyclo [5.4.0] undec-7-ene and first crystallized from ethanol to give 8 g of 2- (7-chloro (1,8-naphthyridin-2-yl) -3-oxy-isoindolin-1-yl-5-methylhexanoate, m.p. 132 ° C.

Example 10 '. The procedure was as in Example 7, except that 6.8 g of 2- (7-methoxy-1,8-naphthyridin-2-yl) -3-hydroxyisoindolin-1-one in 100 cm3 of methylene chloride were used as starting material. 1 triethylamine, 6.4 g of 5-methylhexanyl chloride and 50 mg of 4-dimethylamine-pyridine. The residue obtained after work-up was purified by chromatography on a 100 g silica gel column (0.063-0.2 mm) with a diameter of 2.8 cm (eluted with methylene chloride) and 30 cm3 fractions were collected. Fractions 19 to 94 are combined and concentrated to dryness under reduced pressure (2.7 kPa). The residue obtained is crystallized from 75 cm3 of heptane to give 5.6 g of 2- (7-methoxy-1,8-naphthyridin-2-yl) -3-oxyisoindolin-1-yl-5-methyl- hexanoate with a melting point of 105 eC.

Example 11 The procedure was as in Example 1, but starting from 9.9 g of 3-chloro-2- (7-chloro-1,8-naphthyridin-2-yl) -isoindolin-1-one in 100 cm3 of dimethylformamide anhydride, 5.5 g of 1-propionyl-4-piperidinecarboxylic acid and 4.6 g of 1,8-diazabicyclo [5.4.0] undec-7-ene, and crystallized from ethanol to give 4.9 g of 2 - (7-chloro-1,8-naphthyridin-2-yl) -3-oxo-isoindolin-1-yl-1-propyl-4-piperidylcarboxylate, m.p. 189 ° C.

1-Propionyl-4-piperidylcarboxylic acid can be prepared as follows: A mixture of 25.8 g of 4-piperidinecarboxylic acid and 100 cm 3 of propionic anhydride is heated for 2 hours 30 minutes at about 135 ° C. The reaction mixture is concentrated to dryness under reduced pressure (2.7 kPa) and the oily residue is taken up in 200 cm3 of methylene chloride. The methylene chloride solution obtained is washed 4 times with 80 cm3 of water, dried and concentrated to dryness under reduced pressure (2.7 kPa). The oil obtained is crystallized by shaking in 50 cm3 of ethyl ether. There was thus obtained 5.8 g of 1-propionyl-4-piperidinecarboxylic acid, m.p. 91-94 ° C.

ie 84723

Example 12

The procedure was as in Example 1, but starting from 29.7 g of 3-chloro-2- (7-chloro-1,8-naphthyridin-2-yl) -isoindolin-1-one in 300 cm3 of dimethylformamidian-5 hydride, 13, 1 g of 4-acetamido-butyric acid and 13.7 g of 1,8-diazabicyclo [5.4.0] undec-7-ene, and crystallized from acetonitrile to give 18 g of 2- (7-chloro-1-ene). , 8-Naphthyridin-2-yl) -3-oxo-isoindolin-1-yl-4-acetamide-butyrate, m.p. 186 ° C.

10 Example 13

The procedure was as in Example 1, but starting from 4.95 g of 3-chloro-2- (7-chloro-1,8-naphthyridin-2-yl) -isoindolin-1-one in 60 cm3 of dimethylformamide anhydride, 2.05 g of phenylacetic acid and 2.25 g of 1,8-diaza-15 bicyclo [5.4.0] undec-7-ene. Crystallization from ethyl acetate gave 4.4 g of 2- (7-chloro-1,8-naphthyridin-2-YZ.111-3-oxo-isoindolin-1-yl-phenylacetate, m.p. 222-224 ° C.

Example 14 The procedure was as in Example 1, but starting from 9.9 g of 3-chloro-2- (7-chloro-1,8-naphthyridin-2-yl) -isoindolin-1-one in 100 cm3 of dimethylformamide anhydride, 3.9 g of DL-pyroglutamic acid and 4.6 g of 1,8-diazabicyclo [5.4.0] undec-7-ene. Crystallization from dimethyl-formamide gave 8.8 g of (7-chloro-1,8-naphthyridin-2-yl) -3-oxo-isoindolin-1-yl-5-oxy-2-pyrrolidinicarboxylate, with a melting point of 255 ° C (decomposed).

Example 15

The procedure was as in Example 1, but starting from 9.9 g of 3-chloro-2- (7-chloro-1,8-naphthyridin-2-yl) -isoindolin-1-one in 100 cm3 of dimethylformamide anhydride, 55 g of Ν, Ν-Penta-methylene-meric acid and 4.6 g of 1,8-diazabicyclo [5.4.0] undec-7-ene. Crystallized first from acetonitrile and then from ethanol to give 7.5 g of 2- (7-chloro-1,8-naphthyridin-2-yl) -3-oxy-iso-indolin-1-yl- N, N-pentamethylene succinate with a melting point of 199 eC.

N, N-pentamethylene succinic acid can be prepared as described in D: Pressman, J.M. Bryden, L. Pauling, J. Am. Chem. Soc., 70, 1352 (1948).

Example 16

The procedure was as in Example 1, but starting from 9.9 g of 3-chloro-2- (7-chloro-1,8-naphthyridin-2-yl) -isoindolin-1-one in 100 cm3 of dimethylformamide anhydride, 6, 7 g of 3- (2,6-dimethylpiperidine) propionic acid hydrochloride and 10.7 g of 1,8-diazabicyclo [5.4.0] undec-7-ene and crystallized from ethanol to give 6 g of 2- (7-chloro- 1,8-Naphthyridin-2-yl) -3-oxo-isoindolin-1-yl-15- (2,6-dimethyl-piperidine) -propionate with a melting point of 159 ° C.

3- (2,6-Dimethyl-piperidine) -propionic acid hydrochloride can be prepared using the procedure described in Example 4 for the preparation of 1-methyl-3-piperidinecarboxylic acid hydrochloride, but starting from 12.5 g of ethyl 3 - (2,6-dimethyl-piperidine) -propionate hydrochloride and 35 cm3 of 6N hydrochloric acid solution. There was thus obtained 3- (2,6-dimethyl-piperidine) -propionic acid hydrochloride, m.p. 215 ° C.

: Ethyl 3- (2,6-dimethylpiperidine) propionate hydrochloride can be prepared using the procedure described in Example 6 for the preparation of ethyl 3-diisopropylamine propionate, but starting from 18.1 g of ethyl 3-bromide. propionate, 27 cm 3 of 2,6-dimethyl-30 piperidine and 30 cm 3 of ethanol. The reaction mixture is concentrated to dryness under reduced pressure (2.7 kPa) and the residue obtained is taken up in 50 cm3 of water and 30 cm3 of 4N hydrochloric acid solution. The aqueous phase is washed twice with 80 cm3 of ethyl ether and neutralized by adding 40 cm3 of 4N sodium hydroxide solution. The soluble ____: 35 mat oil was extracted 3 times with 120 cm 3 of ethyl ether; The organic phases are then washed 3 times with 80 cm3 of water and concentrated to dryness under reduced pressure (2.7 kPa) at 40 ° C. The residue is dissolved in 100 cm3 of ethyl ether. To the resulting solution was added 13.4 cm 3 of 4.5N hydrochloric acid-5 gas in ethyl ether. The product precipitates. This was filtered off, washed and air dried. There was thus obtained 14.4 g of ethyl 3- (2,6-dimethylpiperidine propionate hydrochloride, m.p. 146 ° C.

Example 17 The procedure was as in Example 1, but starting from 9.9 g of 3-chloro-2- (7-chloro-1,8-naphthyridin-2-yl) -isoindolin-1-one in 100 cm3 of dimethylformamide anhydride, 6.2 g of 4-piperidinobutyric acid hydrochloride and 10.7 g of 1,8-diazabicyclo [5.4.0] undec-7-ene and crystallized from ethanol gave 9.4 g of 2- (7- chloro-1,8-naphthyridin-2-yl) -3-oxo-isoindolin-1-yl-4-piperidine-butyrate, m.p. 166 ° C.

4-Piperidine-butyric acid hydrochloride can be prepared using the procedure described in Example 4 for the preparation of 1-methyl-3-piperidinecarboxylic acid hydrochloride, but starting from 19.9 g of ethyl 4-piperidine-butyrate and 66.5 cm3 of 6N hydrochloric acid solution and refluxed for 24 hours. There was thus obtained 16.3 g of 4-piperidinobutyric acid hydrochloride having a melting point of 190 ° C.

Ethyl 4-piperidine butyrate can be prepared using the procedure described in Example 6 for the preparation of ethyl 3-diisopropylamine propionate, but starting from 48.8 g of ethyl 4-bromobutyrate, 42.5 g of piperidine and 75 cm3 of ethanol. The reaction mixture is taken up in 200 cm3 of water and 120 cm3 of 4N hydrochloric acid solution. Wash with 150 cm3 of ethyl ether, after which the aqueous phase is made alkaline to a pH of about 9 by adding 4N sodium hydroxide solution. The oil formed was extracted 3 times with ____35 150 cm3 of methylene chloride. The organic phases are combined, washed with water, dried and concentrated to dryness under reduced pressure (2.7 kPa) at 70 ° C. There was thus obtained 47 g of ethyl 4-piperidine butyrate as an oil which was used as such in the synthesis shown.

5 Example 18

The procedure was as in Example 1, but starting from 4.3 g of 3-chloro-2- (7-chloro-1,8-naphthyridin-2-yl) -isoindolin-1-one in 40 cm3 of dimethylformamide anhydride, 2.2 g of 3- (2-oxy-piperidine) -propionic acid and 10 g of 8-diazabicyclo [5.4.0] undec-7-ene. The reaction mixture was taken up in water, extracted with methylene chloride and the solvent was evaporated, after which the resulting residue was crystallized from acetonitrile. The product thus obtained was purified by chromatography on a 100 g silica gel column (0.063-0.2 mm) with a diameter of 2.3 cm (eluted with methylene chloride) and 50 cm3 fractions were collected. Fractions 56 to 64 are combined and concentrated to dryness under reduced pressure (2.7 kPa) at 20 ° C. The resulting residue was crystallized from acetonitrile. There were thus obtained 2.8 g of 2- (7-chloro-1,8-naphthyridin-2-yl) -3-oxo-isoindolin-1-yl-3- (2-oxy-piperidine) -proponate. , with a melting point of 175 eC.

3- (2-Oxy-piperidine) -propionic acid can be prepared as follows: 3.8 g of potassium dissolved in 15 cm3 of water were added to a solution containing 9.2 g of methyl-3- (2-oxy-piperidine) propionate in 40 cm3 of ethanol. The reaction mixture is shaken for 20 hours at about 20 ° C, then evaporated to dryness under reduced pressure (2.7 kPa). The residue is taken up in 100 cm3 of water. The solution obtained is washed with 50 cm3 of ethyl ether and acidified to a pH of about 1 by adding 4N hydrochloric acid solution and extracted 3 times with 100 cm3 of methylene chloride. Wash with water and dry, after which the methylene chloride solution is concentrated to dryness under reduced pressure (2.7 kPa). There was thus obtained 2.3 g of 3- (2-oxy-piperidine) -prop-35-pionic acid, m.p. 105-110 ° C.

22 84723

Methyl 3- (2-oxypiperidine) propionate can be prepared using the method described in H. Takahata et al., Chem. Pharm. Bull., 28 (12), 3632-8 (1980).

Example 19 To a solution of 6.6 g of 3-chloro-2- (7-chloro-1,8-naphthyridin-2-yl) -isoindolin-1-one in 60 cm 3 of dimethylformamide anhydride and kept for about 20 g. At room temperature, 4.2 g of sodium 4-acetyl-1-piperazinyl acetate was added and the reaction mixture was kept at about 20 ° C for 15 hours. Then 3 g of 1,8-diazabicyclo [5.4.0] undec-7-ene was added and shaken again for 24 hours at about 20 ° C. The reaction mixture is taken up in 250 cm3 of water and extracted 3 times with 150 cm3 of methylene chloride. Wash with water, after which the organic phase is concentrated to dryness under reduced pressure (2.7 kPa) and the residue obtained is crystallized from ethanol. There were thus obtained 3.7 g of 2- (7-chloro-1,8-naphthyridin-2-yl) -3-oxo-isoindolin-1-yl-4-acetyl-1-piperazinyl acetate, m.p. ° C.

Sodium 4-acetyl-1-piperazinyl acetate can be prepared as follows: 4.3 g of ethyl 4-acetyl-1-piperazinyl acetate were added to a mixture of 20 cm 3 of ethanol and 20 cm 3 of 1N sodium hydroxide solution. The reaction mixture is shaken for 20 hours at a temperature in the region of 20 ° C and then concentrated to dryness under reduced pressure (2.7 kPa) at 80:25 ° C. The solid obtained is suspended in 80 cm3 of isopropyl oxide and shaken, then filtered and dried. There were thus obtained 4.3 g of sodium 4-acetyl-1-piperazinyl acetate having a melting point of 100-105 ° C.

Ethyl 4-acetyl-1-piperazinyl acetate can be prepared using the method described in D. Nardi and E. Mas-sarani, J. Med. Chem. 14, 635 (1971). . ** ·. Example 20

The procedure was as in Example 1, but starting from 9.9 g of 3-chloro-2- (7-chloro-1,8-naphthyridin-2-23,84723yl) -isoindolin-1-one in 100 cm3 of dimethylformamide anhydride, 4.8 g of 4-proplonamide butyric acid and 4.6 g of 1,8-diaza-bicyclo [5.4.0] undec-7-ene and crystallized from acetonitrile to give 6.6 g of 2- (7- chloro-1,8-naphthyr-5-din-2-yl) -3-oxo-isoindolin-1-yl-4-propionamide butyrate, m.p. 179 ° C.

4-Propionamide butyric acid can be prepared as follows: over 15 minutes, 10.3 g of 4-aminobutyric acid were added to 10 cm 3 of propionic anhydride at about 20 ° C, 10 and then 5 drops of concentrated sulfuric acid (d = 1 , 83) and heated to about 100 ° C for 2 hours. Cool and separate the crystallized solid, wash 5 times with 100 cm3 of ethyl ether and dry. There was thus obtained 9.8 g of 4-propionamidobutyric acid, m.p. 85-90 ° C.

Example 21

To a solution of 9.2 g of 2- (7-methoxy-1,8-naphthyridin-2-yl) -3-hydroxyisoindolin-1-one and 20 cm3 of triethylamine in 150 cm3 of 1.2 -dichloroethane at 20 ° C, 9 g of 2-methylpropoxyacetyl chloride dissolved in 20 cm 3 of 1,2-dichloroethane were added over 20 minutes, followed by 50 mg of 4-dimethylamine-pyridine and refluxed for 16 hours. . The reaction mixture is poured into 250 cm3 of water and extracted with 100 cm3 of methylene chloride. Wash with water, dry and concentrate to dryness under reduced pressure (3 kPa), after which the residue obtained is purified by crystallization twice from ethanol. There was thus obtained 7.9 g of 2- (7-methoxy-1,8-naphthyridin-2-yl) -3-oxy-isodindolin-yl-2-methyl-propoxyacetate, m.p. 114 ° C. .

2-Methyl-propoxyacetyl chloride can be prepared as follows: 5 cm3 of thionyl chloride were added over 15 minutes to a solution of 8.3 g of 2-methyl-propoxyacetic acid in 50 cm3 of chloroform. The reaction mixture 35 is refluxed for 5 hours, then evaporated to dryness under reduced pressure (2.7 kPa). There was thus obtained 7.5 g of 2-methylpropoxyacetyl chloride as an oil, which was used as such in the synthesis shown.

2-Methyl-propoxyacetic acid can be prepared as follows: 200 cm3 of isobutyl alcohol were kept at about 100 ° C and 12.7 g of sodium were added and heated until this dissolved. Then, 23.6 g of chloroacetic acid was added over 1 hour and heating was continued for 2 hours. The reaction mixture was cooled and poured into 250 cm3 of water. The aqueous phase is washed with 200 cm3 of ethyl ether, concentrated to half volume under reduced pressure (3 kPa) and the pH is adjusted to about 1 by adding 1N hydrochloric acid solution. The oil formed is extracted 3 times with 150 cm3 of ethyl ether. The organic phase is washed with water, dried and concentrated to dryness under reduced pressure (2.7 kPa). The residue obtained was distilled under reduced pressure to give 21.8 g of 2-methylpropoxyacetic acid having a boiling point of 92-96 ° C at 0.93 kPa.

Example 22 The procedure was as in Example 1, but 6.6 g of 3-chloro-2- (7-chloro-1,8-naphthyridin-2-yl) -isoindolin-1-one in 60 cm3 of dimethylformamide anhydride were used as starting material, 4.3 g of 1-isopropyl-4-piperidinecarboxylic acid hydrochloride and 7.1 g of 1,8-diazabicyclo [5.4.0] undec-; 25 7-enes. Crystallization from acetonitrile gave 4.1 g of a solid which was dissolved in 120 cm3 of ethanol under reflux: 1.03 g of fumaric acid dissolved in 20 cm3 of ethanol were added. Crystallized from acetonitrile to give 4.9 g of 2- (7-chloro-1,8-naphthyridin-2-yl) -. . . 3-Oxo-isoindolin-1-yl-1-isopropyl-4-piperidyl-fumaric acid, m.p. 184 ° C.

1-Isopropyl-4-piperidinecarboxylic acid hydrochloride can be prepared as described in Example 4 to prepare 1-methyl-3-piperidinecarboxylic acid, but starting from 6.5 g of ethyl 1-isopropyl-84 84 723 4-piperidine carboxylate hydrochloride and 18.6 cm 3 of 6N hydrochloric acid solution. There was thus obtained 4.5 g of 1-isopropyl-4-piperidinecarboxylic acid hydrochloride, m.p. 260-265 ° C.

Ethyl 1-isopropyl-4-piperidyl carboxylate hydrochloride can be prepared as follows: To a solution of 6.15 g of 2-bromopropane in 50 cm 3 of propanol was added over 10 minutes, 15.7 g of ethyl 4 piperidine carboxylate at about 25 ° C. The reaction mixture is refluxed for 48 hours, after which it is concentrated to dryness under reduced pressure (2.7 kPa). The residue is taken up in 150 cm3 of 1.5 N hydrochloric acid solution and the solution obtained is washed twice with 100 cm3 of ethyl ether. The aqueous phase was made alkaline to a pH of about 9 by adding 4N sodium hydroxide solution and extracted 3 times with 100 cm3 of methylene chloride. The organic phase is washed with water, dried and concentrated to dryness under reduced pressure (2.7 kPa) at 40 ° C. The residue obtained is dissolved in 30 cm3 of ethanol. To the resulting solution was added 12 cm3 of 4.5N hydrochloric acid gas in ethyl ether. The precipitate formed was filtered off, washed and dried. There was thus obtained 6.9 g of ethyl 1-isopropyl-4-piperidyl carboxylate hydrochloride, m.p. 195-200 ° C.

Example 23: To a solution of 3.9 g of N-acetyl-β-alanine in 66 cm 3 of dimethylformamide was added 6.6 g of 3-chloro-2- (7-chloro-1,8-naphthyride). -2-yl) -isoindolin-1-one. To the resulting beige suspension was added, drop by drop, 3.8 g of 1,8-diazabicyclo [5.4.0] undec-7-ene and shaken at about 20 ° C for 18 hours. Again, 1 g of N-acetyl-β-alanine and 1 g of 1,8-diazabicyclo [5.4.0] undec-7-ene were added and shaken at about 20 ° C for 24 hours. The reaction mixture is then poured into 130 cm3 of water. The solid obtained is filtered off, washed 3 to 35 times with 25 cm3 of water and purified by flash chromatography (50 kPa) on a 500 g 5 cm diameter silicon column (eluted with dichloromethane-methanol, 95: 5 by volume). 75 cm3 fractions were collected. Fractions 7-9 are combined and concentrated to dryness under reduced pressure (2.7 kPa). The resulting solid was crystallized from acetonitrile to give 3.9 g of 2- (7-chloro-1,8-naphthyridin-2-yl) -3-oxo-isoindolin-1-yl-3-acetamido-propionate. panoate with a melting point of 220 ° C.

N-Acetyl-β-alanine can be prepared using the procedure described in Example 20 for the preparation of 4-propionamide butyric acid, but starting from 8.9 g of β-alanine, 9.6 g of acetic anhydride. There was thus obtained 12.9 g of N-acetyl-β-alanine as an oil which was used as such in the synthesis shown.

15 Example 24

The procedure was as in Example 23, but starting from 5 g of 5-acetamido-pentanoic acid in 66 cm3 of dimethylformamide, 6.6 g of 3-chloro-2- (7-chloro-1,8-naphthyridin-2-yl) -isoindolin-1 -one and 4.7 cm 3 of 1,8-diazabicyclo-20 [5.4.0] undec-7-ene. Crystallized from acetonitrile to give 3.3 g of 2- (7-chloro-1,8-naphthyridin-2-yl) -3-oxo-isoindolin-1-yl-5-acetamido-pentanoate, m.p. melting point was 185 ° C.

5-Acetamido-pentanoic acid can be prepared using the procedure described in Example 20 for the preparation of 4-propionamide butyric acid, but starting from 11.7 g of 5-amine-pentanoic acid and 12.6 g of acetic anhydride. The reaction mixture was concentrated to dryness under reduced pressure (0.05 kPa) to give 6 g of 5-acetamido-pentanoic acid as an oil used as such in the synthesis shown.

Example 25

The procedure was as in Example 1, but starting from 9.9 g of 3-chloro-2- (7-chloro-1,8-naphthyridin-2-35-yl) -isoindolin-1-one in 100 cm3 of dimethylformamide diamine. hydride, 5.2 g of 4-isobutyrylamino-butyric acid and 4.6 g of 1,8-diazabicyclo [5.4.0] undec-7-ene. The residue obtained is crystallized from acetonitrile and purified by chromatography on a 130 g silica column (0.063 0.2 mm) with a diameter of 3 cm (eluted with methylene chloride-methanol, 98: 2 by volume) and 25 cm3 fractions are collected. Fractions 79 to 85 are combined and concentrated to dryness under reduced pressure (2.7 kPa). The resulting residue was crystallized by shaking in isopropyl oxide. There was thus obtained 5.5 g of 10 2- (7-chloro-1,8-naphthyridin-2-yl) -3-oxyisoindolin-1-yl-4-isobutyrylamine butyrate, m.p. 208 ° C.

4-Isobutyrylamino-butyric acid can be prepared as described in Example 21 to prepare 4-propionamide-butyric acid 15, but starting from 10.3 g of 4-amine-butyric acid and 15.8 cm 3 of isobutyric anhydride. There was thus obtained 15.5 g of 4-isobutyrylaminobutyric acid as an oil, which was used as such in the synthesis shown.

Example 26 The procedure was as in Example 1, but starting from 9.9 g of 3-chloro-2- (7-chloro-1,8-naphthyridin-2-yl) -isoindolin-1-one in 100 cm3 of dimethylformamide anhydride, 6 g of 1-butyryl-4-piperidinecarboxylic acid and 4.6 g of 1,8-diazabicyclo [5.4.0] undec-7-ene. The residue obtained was purified by chromatography on a 250 g silica column (0.063-0.20 mm) with a diameter of 4.2 cm (eluted with methylene chloride-methanol, 99: 1 by volume) and 70 cm3 fractions were collected. Fractions 82 to 110 are combined and concentrated to dryness under reduced pressure (2.7 kPa). The residue obtained was taken up in isopropyl oxide with shaking, filtered off and dried. There was thus obtained 6 g of 2- (7-chloro-1,8-naphthyridin-2-yl) -3-oxy-isoindolin-1-yl-1-butyryl-4-piperidinecarboxylate, m.p. 165 ° C. .

35 L-Butyryl-4-piperidylcarboxylic acid can be prepared as described in Example 20 to prepare 4-propionamide butyric acid, but starting from 12.9 g of 4-piperidylcarboxylic acid and 15.8 cm 3 of butyric anhydride. There was thus obtained 16 g of 1-butyl-4-piperidylcarboxylic acid as an oil which was used as such in the synthesis shown.

Example 27

To a solution of 9.9 g of 3-chloro-2- (7-chloro-1,8-naphthyridin-2-yl) -isoindolin-1-one and 6.7 g of 4-di-10-isopropylamino-butyric acid hydrochloride 100 In cm 3 of dimethylformamide, 10.7 g of 1,8-diaza-bicyclo [5.4.0] undec-7-ene was added dropwise, and shaken at about 20 ° C for 20 hours. The reaction mixture is then poured into 130 cm3 of water. The solid obtained is filtered off with a filter pad and dissolved in 200 cm3 of methylene chloride. The organic extract is washed twice with 35 cm3 of 0.1N hydrochloric acid solution, once with 35 cm3 of 0.5N hydrochloric acid solution and then twice with 35 cm3 of water. The organic phase is dried over magnesium sulphate, filtered and concentrated to dryness under reduced pressure (2.7 kPa). The residue is taken up in 200 cm3 of methylene chloride. The organic phase is washed twice with 50 cm3 of aqueous sodium bicarbonate solution. The organic phase is dried over magnesium sulphate, filtered and concentrated to dryness under reduced pressure (2.7 kPa). The resulting residue was crystallized from isopropyl ether. There was thus obtained 7.1 g of 2- (7-chloro-1,8-naphthyridin-2-yl) -3-oxyisoindolin-1-yl-4-dl-isopropylamine butyrate, m.p. 118 ° C. .

4-Diisopropylamine butyric acid hydrochloride can be prepared using the procedure described in Example 4 for the preparation of 1-methyl-3-piperidinecarboxylic acid hydrochloride, but starting from 9.2 g of ethyl 4-diisopropylamine butyrate and 28 g of , 5 cm 3 of 6N hydrochloric acid solution and refluxed for 6 hours. There was thus obtained 8 g of 4-diisopropylamine butyric acid 29,84723 hydrochloride, m.p. 136 ° C.

Ethyl 4-di-isopropylamine butyrate can be prepared as follows: To a solution of 39 g of ethyl 4-bromobutyrate in 80 cm 3 of ethanol was added dropwise 40.4 g of diisopropylamine. The resulting solution was refluxed for 6 hours. The insoluble matter formed is filtered off and the filtrate is concentrated to dryness under reduced pressure (2.7 kPa). The residue is taken up in 15 cm3 of distilled water and 100 cm3 of 4N hydrochloric acid solution. The aqueous phase is washed 3 times with 75 cm3 of ethyl ether and made alkaline by adding 10N sodium hydroxide solution. The oil formed is extracted 3 times with 75 cm3 of ethyl ether. The formed oil was extracted 3 times with 75 cm3 of ethyl ether. The organic phase obtained is concentrated to dryness under reduced pressure (2.7 kPa). There was thus obtained 9.2 g of ethyl 4-diisopropylamine butyrate as an oil which was used as such in the synthesis shown.

Example 28

To a solution of 12.5 g of 2- (7-chloro-1,8-naphth-20-thyridin-2-yl) -3-hydroxyisoindolin-1-one in 600 cm 3 of methylene chloride was added 12.2 g of triethylamine. , 90 cm 3 of pyridine and 9.7 g of 3-methylbutyryl chloride at a temperature of about 25 ° C. Shaken for 4 hours at about 25 ° C, then 9.7 g of 3-methyl-butyryl chloride were added again and shaken for 16 hours at the same temperature. The reaction mixture is then concentrated to dryness under reduced pressure (3 kPa) and the residue is taken up in 500 cm3 of water. The insoluble matter formed was filtered off, washed, dried and crystallized from a mixture of isopropyl oxide and ethyl acetate (50:50 by volume). There was thus obtained 7.9 g of 2- (7-chloro-1,8-naphthyridin-2-yl) -3-oxyisoindolin-1-yl-3-methylbutyrate, m.p. 154 ° C.

Example 29 35 To a solution of 3.2 g of 2- (7-chloro-1,8-naphth-8,84723 thyridin-2-yl) -3-hydroxyisoindolin-1-one in 160 cm 3 of methylene chloride was first added cm 3 of pyridine and after 30 min 5.5 g of propionyl chloride and the temperature was maintained at about 25 ° C. The mixture is shaken for 3 hours at this temperature and 100 cm3 of water are added. The organic phase is decanted, washed with water, dried and concentrated to dryness under reduced pressure (2.7 kPa). The resulting residue was crystallized first from isopropyloxide, then from a mixture of isopropyloxide and ethyl acetate (25:75 by volume). There was thus obtained 1 g of 2- (7-chloro-1,8-naphthyridin-2-yl) -3-oxyisoindolin-1-yl propionate, m.p. 160 ° C.

Example 30

Proceed as in Example 29, but starting from 6.4 g of 2- (7-chloro-1,8-naphthyridin-2-yl) -3-hydroxy-isoindolin-1-one in 320 cm3 of methylene chloride, 48 cm3 pyridine and 12.8 g of butyryl chloride. Crystallized first in isopropyl oxide, then twice in acetonitrile to give 3.4 g of 2- (7-chloro-18-naphthyridin-2-yl) -3-oxy-isoindolin-1-yl butyrate, which melting point was 140 ° C.

Example 31

The procedure was as in Example 1, but starting from 9.9 g of 3-chloro-2- (7-chloro-1,8-naphthyridin-2-25yl) -isoindolin-1-one in 100 cm3 of dimethylformamide anhydride, 4, 25 g of 4-cyclohexanone carboxylic acid and 4.6 g of 1,8-diazabicyclo [5.4.0] undec-7-ene. Crystallized from acetonitrile to give 8.5 g of 2- (7-chloro-1,8-naphthyridin-2-yl) -3-oxo-isoindolin-1-yl-4-oxy-cyclo-30-hexane-1-carboxylate, m.p. was 203 ° C.

Example 32

The procedure was as in Example 7, but starting from 8.55 g of 2- (7-bromo-1,8-naphthyridin-2-yl) -3-hydroxyisoindolin-1-one in 110 cm 3 of methylene chloride, .35 11.1 g of triethylamine, 7 g of 5-methyl-hexanyl chloride 3i 84723 and 50 mg of 4-dimethylamine-pyridine. The residue was crystallized first from hexane and then from ethanol to give 7.5 g of 2- (7-bromo-1,8-naphthyridin-2-yl) -3-oxyl-1-indololin-1-yl-5-methylhexanoate. , m.p. 136 ° C.

2- (7-Bromo-1,8-naphthyridin-2-yl) -3-hydroxyisoinindolin-1-one can be prepared as disclosed in BE Patent 815,019.

Example 33 A suspension of 6.15 g of 3-hydroxy-2- (7-methoxy-1,8-naphthyridin-2-yl) -isoindolin-1-one in 50 cm3 of dimethylformamide anhydride was added over 15 minutes. 96 g of an oily sodium hydride suspension (50% by weight) and the temperature was maintained at about 0 [deg.] C. and shaken again for 30 min at 0 [deg.] C. Then 2.9 cm 3 of diethyl chlorophosphate were added dropwise over 30 minutes at a temperature of about 0 ° C. To the resulting solution was added, at about 0 ° C, a solution of 4-acetylamine butanoate prepared from 2.9 g of 4-acetamidobutyric acid / 30 cm 3 of dimethylformamide anhydride and 0.96 g of an oily sodium hydride suspension (50% by weight). The mixture was shaken for 1 hour at 0 ° C and then for 20 hours at about 20 ° C, and finally for 4 hours at 80 ° C. The reaction mixture is poured into 400 cm3 of water and extracted 3 times with 200 cm3 of methylene chloride. The organic extracts are combined and washed with water, dried and concentrated to dryness under reduced pressure (2.7 kPa). The residue obtained is purified by chromatography on a 350 g silica column (0.063-0.2 mm) with a diameter of 5 cm (eluted with methylene chloride-30-dimethanol, 99: 1 by volume) and 100 cm3 fractions are collected. Fractions 23 to 39 are combined and concentrated to dryness under reduced pressure (2.7 kPa) at 40 [deg.] C., the residue is crystallized from acetonitrile. There was thus obtained 2 g of 2- (7-methoxy-1,8-naphthyridin-2-yl) -3-oxyisoindolin-1-35yl-4-acetylamine butyrate, m.p. 190 ° C.

32 84723

Example 34

The procedure was as in Example 7, but starting from 3.7 g of 2- (7-methyl-1,8-naphthyridin-2-yl) -3-hydroxyisoindolin-1-one, 7.8 g of 5-methylhexanyl-5 chloride , 12 cm 3 of triethylamine and 50 mg of 4-dimethylamine pyridine. The resulting solid was treated and crystallized from methylcyclohexane to give 3.8 g of 2- (7-methyl-1,8-naphthyridin-2-yl) -3-oxo-isoindolin-1-yl-5-methyl-hexanoate, m.p. was 144 ° C.

3-Hydroxy-2- (7-methyl-1,8-naphthyridin-2-yl) isoindolin-1-one can be prepared using as disclosed in DE Patent 2,423,650.

5-Methyl-hexanyl chloride can be prepared using Goerner G. L. et al., J. Org. Chem., 15, 24, 1561 (1959).

Example 35

The procedure was as in Example 1, but starting from 9.9 g of 3-chloro-2- (7-chloro-1,8-naphthyridin-2-yl) -isoindolin-1-one in 100 cm3 of dimethylformamide-20 hydride, 4, 8 g of 4- (N-methylacetamide) butyric acid and 4.6 g of 1,8-diazabicyclo [5.4.0] undec-7-ene. The oily residue obtained is purified by chromatography on a 150 g silica column (0.063-0.2 mm) with a diameter of 3 cm (eluted with methylene chloride-methanol, 99: 1 by volume) and 30 cm3 of fractions are collected. Fractions 76-175 were concentrated to dryness under reduced pressure (2.7 kPa) at 60 ° C and crystallized from ethyl ether to give 3.1 g of 2- (7-chloro-1,8-naphthyridin-2-yl) -3-oxy- isoindolin-1-yl-4- (N-methylacetamido) butyrate, m.p. 170 ° C.

4- (N-methylacetamide) butyric acid can be prepared as follows: To a solution of 15.4 g of 4- (N-methylacetamide) butyric acid hydrochloride in 200 cm 3 of 2.5 N sodium hydroxide solution and kept for about 5 at eC, 11.8 g of acetyl chloride were added over 35 hours. The mixture was shaken again at 33,84723 for 30 min at about 5 ° C and acidified to a pH of about 1 by the addition of 12N hydrochloric acid solution. The mixture is concentrated to dryness at 80 [deg.] C. under reduced pressure (2.7 kPa) and the residue obtained is taken up in 150 cm <3> of ethanol. The solid 5 is filtered off and the filtrate is concentrated to dryness at 60 [deg.] C. under reduced pressure, and the residue is taken up in 150 cm <3> of methylene chloride. The organic phase is dried over magnesium sulphate and concentrated to dryness at 60 ° C under reduced pressure (2.7 kPa). There was thus obtained 19 g of 4- (N-methylacetamide) butyric acid as an oil which was used as such in the synthesis shown.

Example 36

The procedure was as in Example 7, but starting from 5 g of 2- (7-fluoro-1,8-naphthyridin-2-yl) -3-hydroxy-15-isoindolin-1-one in 60 cm3 of methylene chloride, 6.5 g triethylamine, 3.66 g of 4-methylpentanyl chloride and 10 mg of 4-dimethylamine pyridine. Crystallization from ethanol gave 1.2 g of 2- (7-fluoro-1,8-naphthyridin-2-yl) -3-oxy-isoindolin-2-yl-4-methylpentanoate having a melting point of 154 ° C.

2- (7-Fluoro-1,8-naphthyridin-2-yl) -3-hydroxy-isoindolin-1-one can be prepared as follows: To a suspension containing 16.6 g of 2- (7-fluoro-1-fluoro- (8-naphthyridin-2-yl) -isoindoline-1,3-dione in a mixture of 90 cm3 of methanol anhydride 25 and 90 cm3 of dioxane, 2.3 g of potassium tetrahydride borate were added in small portions at about 20 ° C and the resulting suspension was shaken 3 hours at about 20 ° C. The reaction mixture is then poured into a mixture of 120 g of ice and 240 cm3 of water. The insoluble matter is filtered off, washed 3 times with 50 cm3 of water, air-dried and crystallized from acetonitrile. There was thus obtained 10.3 g of 2- (7-fluoro-1,8-naphthyridin-2-yl) -3-hydroxyisoindolin-1-one, m.p. 246 ° C.

2- (7-Fluoro-1,8-naphthyridin-2-yl) -isoindoline-1,3-dione can be prepared as follows: A suspension containing 20.6 g of 2- (7-chloro- 1,8-Naphthyridin-2-yl) -isoindoline-1,3-dione in 270 cm3 of nitrobenzene anhydride, kept under argon, 15 g of potassium fluoride were added and the reaction mixture was refluxed with shaking for 22 hours. The reaction mixture is cooled to about 80 ° C and concentrated to dryness under reduced pressure (0.13 kPa) at 80 ° C. The residue obtained is taken up in 70 cm3 of ethyl acetate. The insoluble matter is filtered off, washed first with 30 cm3 of ethyl acetate and then with 10 cm3 of 30 cm3 of water and dried in air. There was thus obtained 16.9 g of 2- (7-fluoro-1,8-naphthyridin-2-yl) -isoindoline-1,3-dione, m.p. 264 ° C.

2- (7-Chloro-1,8-naphthyridin-2-yl) -isoindoline-1,3-dione can be prepared using the method described in BE-A-153535.

Example 37

A solution of 25 mg of 2- (7-chloro-1,8-naphthyridin-2-yl) -3-oxo-1-isoindolinyl-4-acetamidobutyrate in 10 cm 3 of a mixture of hexane and ethanol (50-50 vol.) The Kro-20 was chromatographed in a stationary phase comprising tris- (phenylcarbamate) cellulose absorbed on macroporous silica in a column 2.2 cm in diameter and 25 cm in length. Eluted with a mixture of hexane and ethanol, followed by UV determination at cellulose-25 at 360 nm. The volume flow was 9 cm 3 / min. The right-turning isomer eluted in 20 minutes, followed by the left-turning isomer. The corresponding eluates were evaporated to dryness under reduced pressure (2.7 kPa) at 45 ° C. There was thus obtained 8 mg of (-) 2- (7-chloro-1,8-naphthyridin-2-yl) -3-oxo-1-isoindolinyl-4-acetamidobutyrate, m.p.

199 ° C and 7 mg of (+) 2- (7-chloro-1,8-naphthyridin-2-yl-3-oxo-1-isoindolinyl-4-acetamidobutyrate, mp 200 ° C.

Racemic 2- (7-chloro-1,8-naphthyridin-2-yl) -3-oxo-1-isoindolinyl-4-acetamidobutyrate can be prepared as in Example 12.

35 84723

Example 38

The procedure was as in Example 37, but starting from 25 mg of 2- (7-chloro-1,8-naphthyridin-2-yl) -3-oxo-1-isoindolinyl-4-propionamidobutyrate. There were thus obtained 8 mg of (-) 2- (7-chloro-1,8-naphthyridin-2-yl-3-oxo-1-isoindolinyl-4-propionyldobutyrate, mp 205 ° C and 8 mg of (+) 2- (7-chloro-1,8-naphthyridin-2-yl) -3-oxo-1-10-indolinyl-4-propionamidobutyrate, mp 204 ° C.

Racemic 2- (7-chloro-1,8-naphthyridin-2-yl) -10-oxo-1-isoindolidinyl) -4-propionamidobutyrate can be prepared as in Example 20.

Claims (6)

A process for the preparation of therapeutically active 2- (1,8-naphthyridin-2-yl) -isoindolin-1-ones of formula (I) R 1 m OCOR wherein R is a C 1-7 alkyl group which may be substituted by an alkoxy or dialkylamino group or an alkylcarbonylamino group, the amino moiety of which may be substituted by a C 1-4 alkyl, piperidino or piperidyl group, or R is 4 -piperidyl, wherein the alkyl groups are straight-chain or branched and the piperidino and 4-piperidyl group may be substituted by one or two alkyl groups and Rx is a halogen atom or a C 1-4 alkyl or C 1-4 alkoxy group, and pharmaceutically acceptable acid addition salts and optical isomers thereof known to be that A. To prepare compounds of formula (I) wherein R is as defined above and R 1 is a halogen atom or an alkyl group, an acid of formula (II) is obtained. R-COOH (II) wherein R is as defined above, or an alkali metal salt of this acid to react with a compound of formula (lii) 35 37 84723 5 α> ζχ \ - * αιΐ) C1 wherein R / is a halogen atom or an alkyl group , after which the compound thus obtained is isolated and, if desired, converted into a pharmaceutically acceptable acid addition salt, or B. To prepare compounds of formula (I) wherein R and R 1 are as defined above, a compound of formula (V) RCO-X (V) is obtained. ) wherein R is as defined above and X is a halogen atom or a reactive ester residue, to react with a compound of formula (IV) 0: ¾ - Öv> ~ fYV · '™ OH where R: is as defined above, followed by 30 the compound obtained is isolated and, if desired, converted into a pharmaceutically acceptable acid addition salt, or C. for the preparation of compounds of formula (I) wherein R and R 1. mean the same as above, reacting an alkali metal salt of an acid of formula (II) R-COOH (II) wherein R is as defined above with a compound of formula (VI) 5 ^ γ, _ € 0 ~ ·· ™ 10 I O-P- (OR) 11 Z 0 wherein Rx is as defined above and R4 is a straight-chain or branched C1-4 alkyl group or a phenyl group, after which the compound thus obtained is isolated and, if desired, converted into a pharmaceutically acceptable acid addition salt. 39 8 4 7 2 3 For the preparation of therapeutically active 2- (1,8-naphthyridin-2-yl) -isoindolin-1-one with formula (I) 5 Ογ-ocr · 'OCOR color R är en C1.7 -alkyl group, a radical moiety substituted by an alkoxy- or dialkylamino group, a stem which may be substituted by a C1-4-alkyl-, piperidino- or piperidyl group or R4 by 4-piperidinyl, dyes by an alkyl group or a ring or a pyridine group - and 4-piperidyl groups which may be substituted by an alkyl group and Rx is a halogen atom or a C 1-4 alkyl or C 1-4 alkoxy group, as well as a pharmaceutically acceptable hydrogenation moiety and an optical isomer, which is converted to A. For the preparation of compounds of formula (I), 25 color R is an anhydrous or an alkyl group and Rx is a halogen atom or an alkyl group, the same is used for the formulation (II) R-COOH (II) 30 color R is an anhydrous or an alkyl group alkali metal salt in the form of a salt, which is obtained from the formulation (III) 35 40 84723 o 5 0c | / n —— ri (iii! Cl color R'x is a halogen atom or an alkyl group, varent 10 of which may be isolated in the form of an orthogonal compound, or a batch of a pharmaceutical form of a compound, or B. For the production of a compound of formula I, color R Rx is an anhydrous compound having an odor of 15 or more halogen atoms 20 or an halogen atom 20 or a reactive ester, with an amylate (IV) I “ Ογ -QQr *. OH 30 color Rx is an anhydrous form, which may be used in combination with a formulation (I), the color R and the anhydrous form of the formulation (I), omsätts et alka-; 35 limetalsalt av en syra med formuleln (II) ι - 4i 84723 R-COOH (II) color R har ovan angivna betydelse, med en förening med 5 formuleln (VI) 0 0γ · '· "° -p- (OR4) 2 0 or R1 is a solid and R4 is preferably substituted with a C1-4 alkyl group or a phenyl group, which may then be used as an intermediate in the pharmaceutical formulation.